X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN LTD AJANTA PHARMA/
LUPIN LTD
 
P/E (TTM) x 20.3 28.0 72.5% View Chart
P/BV x 4.8 2.9 162.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 AJANTA PHARMA   LUPIN LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
LUPIN LTD
Mar-18
AJANTA PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,8181,465 124.1%   
Low Rs1,106727 152.1%   
Sales per share (Unadj.) Rs239.5349.6 68.5%  
Earnings per share (Unadj.) Rs52.85.6 949.9%  
Cash flow per share (Unadj.) Rs59.529.6 201.2%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs230.0300.3 76.6%  
Shares outstanding (eoy) m88.77452.08 19.6%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x6.13.1 194.7%   
Avg P/E ratio x27.7197.2 14.0%  
P/CF ratio (eoy) x24.637.1 66.3%  
Price / Book Value ratio x6.43.6 174.2%  
Dividend payout %090.0 0.0%   
Avg Mkt Cap Rs m129,782495,502 26.2%   
No. of employees `0006.817.0 39.9%   
Total wages/salary Rs m3,76528,647 13.1%   
Avg. sales/employee Rs Th3,128.49,273.6 33.7%   
Avg. wages/employee Rs Th554.01,681.0 33.0%   
Avg. net profit/employee Rs Th689.7147.4 467.8%   
INCOME DATA
Net Sales Rs m21,258158,042 13.5%  
Other income Rs m2421,504 16.1%   
Total revenues Rs m21,499159,545 13.5%   
Gross profit Rs m6,58431,475 20.9%  
Depreciation Rs m59610,859 5.5%   
Interest Rs m42,044 0.2%   
Profit before tax Rs m6,22620,076 31.0%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m1,5392,885 53.4%   
Profit after tax Rs m4,6862,513 186.5%  
Gross profit margin %31.019.9 155.5%  
Effective tax rate %24.714.4 172.1%   
Net profit margin %22.01.6 1,386.7%  
BALANCE SHEET DATA
Current assets Rs m12,236122,095 10.0%   
Current liabilities Rs m3,46150,956 6.8%   
Net working cap to sales %41.345.0 91.7%  
Current ratio x3.52.4 147.6%  
Inventory Days Days6085 71.2%  
Debtors Days Days84120 70.5%  
Net fixed assets Rs m11,140129,876 8.6%   
Share capital Rs m177904 19.6%   
"Free" reserves Rs m20,237134,866 15.0%   
Net worth Rs m20,414135,771 15.0%   
Long term debt Rs m1064,245 0.0%   
Total assets Rs m24,486263,054 9.3%  
Interest coverage x1,519.410.8 14,036.8%   
Debt to equity ratio x00.5 0.1%  
Sales to assets ratio x0.90.6 144.5%   
Return on assets %19.21.7 1,106.0%  
Return on equity %23.01.9 1,240.5%  
Return on capital %30.53.7 819.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66753,141 22.0%   
Fx outflow Rs m1,61619,335 8.4%   
Net fx Rs m10,05233,807 29.7%   
CASH FLOW
From Operations Rs m2,85417,512 16.3%  
From Investments Rs m-2,604-14,073 18.5%  
From Financial Activity Rs m-2-14,921 0.0%  
Net Cashflow Rs m248-11,482 -2.2%  

Share Holding

Indian Promoters % 73.8 46.6 158.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 31.9 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.1 168.3%  
Shareholders   20,968 98,259 21.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   MERCK LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 25, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS